Clinical study of Russian class III antiarrhythmic agent, nibentan, in supraventricular arrhythmia management

Aim. To study clinical efficacy of a new, class III, antiarrhythmic agent, nibentan, in various supraventricular (SV) cardiac arrythmias. Material and methods. In total, 153 patients with atrial fibrillation, atrial flutter, or SV tachycardia were examined. Electrocardiography monitoring, echocardiography, electrolyte balance assessment, biochemical blood assay were performed. Left ventricular (LV) kinetics and perfusion was measured by myocardial computer scintigraphy method. The results were processed with 4DM spect program. Results. Nibentan demonstrated high antiarrhythmic activity in various SV cardiac arrhythmias No significant effects on central hemodynamics and LV myocardial perfusion were observed. Conclusion. In this trial, a new medication, nibentan, demonstrated the qualities of a true class III antiarrhythmic agent.